Estrogen News and Research

Latest Estrogen News and Research

Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD

Aeterna Zentaris Inc. today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD).

27 Jul 2011

Bionovo completes 13 weeks repeat dose animal toxicology studies for Menerba

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today the successful completion of 13 weeks repeat dose animal toxicology studies with Menerba.

25 Jul 2011

Sigma Life Science releases breast cancer-specific knockout and knockin cell lines for drug research

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich, today announced the expansion of its CompoZr® Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research.

22 Jul 2011

Experts present new research at 2011 Alzheimer's Association ICAD

Experts from the Center of Excellence on Brain Aging at NYU Langone Medical Center will present new research at the 2011 Alzheimer's Association International Conference on Alzheimer's disease to be held in Paris, France from July 16 - 21.

21 Jul 2011

Birth control pills may reduce woman's bone density

Birth control pills may reduce a woman's bone density, according to a study published online July 13 in The Journal of Clinical Endocrinology and Metabolism by Group Health Research Institute (GHRI) scientists.

20 Jul 2011

Researchers identify potential therapeutic target for ER-negative breast cancer

Using a new in vivo screening system, Whitehead Institute researchers have identified a protein in the serine biosynthesis pathway that is essential in estrogen receptor (ER)-negative breast cancer—a notoriously difficult disease to treat associated with low five-year survival rates.

19 Jul 2011

Scientists identify new metabolic pathway for breast cancer

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today a publication in the journal Nature that identifies dysregulated activity of the serine pathway as a novel metabolic target in certain breast cancers.

15 Jul 2011

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint.

15 Jul 2011

Treatment with estrogen dramatically lowers rates of stomach cancer in male mice

Several types of cancer, including stomach, liver and colon, are far more common in men than in women. Some scientists have theorized that differences in lifestyle, such as diet and smoking, may account for the discrepancy, but growing evidence suggests that the differences are rooted in basic biological differences between men and women.

14 Jul 2011

Progesterone could fight against neuroblastoma

High doses of the hormone progesterone can kill neuroblastoma cells while leaving healthy cells unscathed, scientists at Emory University School of Medicine have found in laboratory research.

14 Jul 2011

Penis size linked to finger length: Study

A new South Korean study shows that the ratio of the length of a man's index finger to that of his ring finger is linked with penis size. The lower the ratio the longer the penis, say researchers. The study was published in the Asian Journal of Andrology.

7 Jul 2011

Women more likely to survive after major gastrointestinal surgeries than men

In the first study to consider the impact of gender on patient outcomes in major gastrointestinal surgeries, researchers at UC San Diego Health System have found that women are more likely to survive after the procedure than men.

1 Jul 2011

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.

28 Jun 2011

Researchers demonstrate how Runx3 protein could suppress breast cancer tumor growth

Researchers have identified a protein long known to regulate gene expression as a potent suppressor of breast cancer growth. Their study, in the journal Oncogene, is the first to demonstrate how this protein, known as Runx3, accomplishes this feat.

27 Jun 2011

NJIT research professor's work on sugar-based chemicals tops ACS must-read list

NJIT Research Professor Mike Jaffe's recent book chapter about sugar-based chemicals is topping the American Chemical Society (ACS) book series' must-read list.

22 Jun 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx, Inc., announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.

20 Jun 2011

Scientists create first roadmap to understand estrogen signaling in breast cancer cells

The first roadmap to mathematical modeling of a powerful basic "decision circuit" in breast cancer has been developed and published in Nature Reviews Cancer.

18 Jun 2011

Food-based soy products safe for breast cancer survivors, expert says

There has been widespread concern about whether it is safe for women with breast cancer to eat soy. An excellent source of fiber, vitamin B6 and protein, soy is usually associated with a health-conscious diet, but research concerning its safety has been mixed.

17 Jun 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

Flaxseed of no use in menopausal hot flashes: Study

Flaxseed has been the latest agent that has been tried in treating menopausal hot flashes and it is seen that it does not reduce the incidence of the unpleasant symptoms.

7 Jun 2011